Comparative Pharmacology
Head-to-head clinical analysis: DESCOVY versus SYMTUZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESCOVY versus SYMTUZA.
DESCOVY vs SYMTUZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DESCOVY is a fixed-dose combination of emtricitabine and tenofovir alafenamide. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase by competing with the natural substrate deoxycytidine-5'-triphosphate and incorporating into viral DNA, causing chain termination. Tenofovir alafenamide is a prodrug of tenofovir, which is also an NRTI; it is taken up by cells and converted to tenofovir diphosphate, which inhibits HIV-1 reverse transcriptase via chain termination after incorporation into viral DNA.
SYMTUZA is a fixed-dose combination of darunavir (a HIV-1 protease inhibitor), cobicistat (a CYP3A inhibitor), emtricitabine (a nucleoside reverse transcriptase inhibitor), and tenofovir alafenamide (a nucleotide reverse transcriptase inhibitor). Darunavir inhibits HIV-1 protease, preventing cleavage of viral polyproteins and resulting in immature, non-infectious virus. Emtricitabine and tenofovir alafenamide inhibit HIV reverse transcriptase by competing with natural substrates and causing DNA chain termination. Cobicistat inhibits CYP3A, boosting darunavir exposure.
One tablet (emtricitabine 200 mg / tenofovir alafenamide 25 mg) orally once daily with or without food.
One tablet (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg) orally once daily with food.
None Documented
None Documented
TAF: 0.51 hours (intracellular tenofovir diphosphate ~150 hours). FTC: 10 hours (intracellular triphosphate >39 hours). Clinical context: Long intracellular half-life supports once-daily dosing.
Darunavir: 15 hours (when boosted with cobicistat). Cobicistat: 3-4 hours. Emtricitabine: 10 hours. Tenofovir alafenamide: 0.5 hours (active metabolite tenofovir diphosphate intracellular half-life >60 hours).
Tenofovir alafenamide (TAF): 80% excreted renally as unchanged drug via glomerular filtration and active tubular secretion; 15% recovered in feces. Emtricitabine (FTC): 70% excreted renally as unchanged drug via glomerular filtration and active tubular secretion; 14% as metabolites; remainder in feces.
Darunavir: ~80% feces (mostly metabolites), ~14% urine (unchanged 1.5%). Cobicistat: ~86% feces, ~8% urine. Emtricitabine: ~86% urine (unchanged), ~14% feces. Tenofovir alafenamide: ~31% urine, ~47% feces (as tenofovir).
Category C
Category C
Antiretroviral
Antiretroviral